Adial Pharmaceuticals, Inc. (ADIL) Stock

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing therapeutics aimed at addressing addiction and associated disorders. At the forefront of its pipeline is AD04, a selective serotonin-3 antagonist currently undergoing Phase III clinical trials for the treatment of alcohol use disorder. Beyond addiction treatment, Adial Pharmaceuticals is actively developing drug candidates focused on non-opioid pain reduction and tackling various other diseases and disorders.

Founded in 2010 and headquartered in Charlottesville, Virginia, Adial Pharmaceuticals continues to expand its research and development efforts with a strong commitment to improving outcomes for patients affected by addiction and related conditions. The company's innovative approach centers on leveraging scientific advancements to develop effective treatments that meet significant unmet medical needs.

In addition to its clinical advancements, Adial Pharmaceuticals is positioned strategically within the biopharmaceutical landscape, aiming to establish itself as a leader in addiction treatment and therapeutic innovation. With a clear mission to bring novel therapies to market, the company remains focused on creating value for patients, healthcare providers, and stakeholders alike.